| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8743824 | Transplant Immunology | 2017 | 25 Pages |
Abstract
Grafalon and Thymoglobulin seem to be equivalent to prevent acute rejection. CMV disease is more frequent in Thymoglobulin-treated patients. One year post-transplant immune profile profoundly differs according to the type of ATG.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jamal Bamoulid, Thomas Crepin, Emilie Gaiffe, Caroline Laheurte, Bruno Moulin, Luc Frimat, Philippe Rieu, Christiane Mousson, Antoine Durrbach, Anne-Elisabeth Heng, Jean-Michel Rebibou, Philippe Saas, Cécile Courivaud, Didier Ducloux,